Texas Cord Blood Bank is a division of the South Texas Blood & Tissue Center. The Texas legislature approved the creation of the program. The director of operations is Ray Adams.
Since immune types are specific to ethnic groups, the Texas Cord Blood Bank is strategically located to collect cord blood units that reflect the rich ethnic diversity of Texas. In the past 11 years, the Texas Cord Blood Bank has been recognized nationally and internationally for innovation in the field of regenerative medicine using cord blood collected from the placenta following healthy live births. Cord blood, rich in blood-making cells, can be used to treat patients with certain cancers and fatal blood disorders.
Collection hospitals as of July 2013:
- Christus Santa Rosa - New Braunfels
- Medical City Hospital - Dallas
- Methodist Hospital - San Antonio
- Metropolitan Methodist Hospital - San Antonio
- Mission Trail Baptist - San Antonio
- North Central Baptist - San Antonio
- Providence Health Care - Waco
- St. David's Medical Center - Austin
- St. David's North Austin Medical Center - Austin
- St. Luke’s Episcopal/Texas Children’s Hospital - Houston
- Texas Health Presbyterian - Allen
- Texas Health Presbyterian - Rockwall
- University Hospital - San Antonio
- Valley Baptist - Brownsville
- Valley Baptist - Harlingen
- Women's Hospital at Renaissance - Edinburg
The Texas Cord Blood Bank (TCBB) has been a leader among public banks at developing innovative partnerships with research programs that help to fund the collection of donations.
- - March 2011- State of Texas cut $2 million from the funding for TCBB
- - May 2012 - TCBB announces clinical supply and research collaboration agreement with Saneron CCEL Therapeutics, a Florida company that uses cord blood stem cells to develop treatments for neurological conditions such as Stroke, ALS, and Alzheimer's disease.
- - Oct. 2012 - TCBB announces Human umbilical cord blood stem cell research collaboration agreement with StemBioSys, a San Antonio company that has developed a 3D scaffold for the rapid expansion of stem cell populations.
Carmen Davila, VP, Corporate Communications